Granules IndiaQ1 FY27
Granules India Q1 FY27 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Price: ₹846P/E: 32.7Market Cap: ₹21.3K CrSector: Pharmaceuticals & Biotechnology
Management growth scorecard
Revenue
Category 2
Margin
Category 3
Fundraise
N/A
Order
N/A
Capex
Yes
1 of 3 growth signals are positive — mixed outlook.
Full analysisRevenue guidance
Category 2- →Granules India expects continued strong growth in FY27, building on a 22% YoY growth in Q1 FY27 and similar growth trajectory in prior quarters.
- →Complex generics, now 50% of finished dosages (up from 39% a year ago), are a key growth driver with sustainable growth expected.
- →Europe is seen as a strong growth market with a positive upward trajectory due to increased demand for products filed in the past.
- →Controlled substance products are growing, with existing products expanding market share and 1-2 new controlled substance launches expected starting FY28.
- →Peptide CDMO business aims for a 5x revenue increase over 5 years, targeting $50 million revenue with 30%+ EBITDA margin mid-way in this journey.
- →Overall, Granules India is confident of maintaining gross margins and EBITDA growth with steady capex supporting expansion.
Margin guidance
Category 3- →Granules India anticipates continued strong revenue growth, with 22% YoY growth in Q1 FY27 and similar growth trajectory expected for full FY27 (Page 6).
- →EBITDA margins are expected to remain stable around 22%-23%, supported by improving product mix favoring complex generics (Page 6).
- →Operating profitability should benefit from gross margin expansion driven by complex generics and calibrated pricing actions amidst RM cost pressures (Page 6).
- →Medium-term growth is driven by complex generics, oncology launches, controlled substances, and expansion of peptide CDMO business (Pages 13-14, 4).
- →R&D investment remains steady at around 5.5%-6% of sales, underpinning future differentiated product launches (Page 14).
- →ROCE improved to 18% and expected to progress steadily with scaling of Genome Valley and peptide platform (Page 7).
- →Overall, Granules projects continued margin accretion and sustainable profitability growth through diversification and complex product portfolio (Pages 4, 14).
3 more insights locked — sign up free to unlock
Fundraise plans
- →The transcript does not mention any current or future plans for fundraising through debt or equity.
- →The company reports a healthy balance sheet with net debt at INR1,012 million in Q1 FY27, down from INR4,021 million at FY26 close, indicating a low debt level.
- →The net debt to EBITDA ratio stands at approximately 0.07x, effectively making the company nearly debt-free.
- →Management expresses comfort in funding growth, capacity expansions, and R&D from the existing financial position.
- →Capex guidance for FY27 is INR600 crores, with no indication of additional fundraising.
- →Management focus is on capital efficiency and conservative capital allocation, with dividend policy under internal review but no mention of new capital raising.
- →Overall, no explicit plans or announcements related to raising new debt or equity are disclosed.
Order book
- →Granules India Limited has about 23-24 ANDA filings still pending approval.
- →Of these, 9 products are pending facility approval.
- →Approximately 9 products are pending approvals, primarily due to IP-related issues.
- →An additional 5 products from the U.S. are still pending approval; some are IP-based while others await regulatory approval.
- →In the oncology segment, 2 ANDAs have been filed in the U.S. and Europe, with around 14 extensions of the same dossiers in various countries.
- →The company has 9 to 13 oncology products at various stages of development.
- →Controlled substances have 4-5 launches pending, with 1 to 2 expected in the next 1.5 to 2 years.
- →No new controlled substance launches are expected in FY27; growth will come from existing products.
Capex plans
Yes- →Capex in Q1 FY27 was INR 89 crores; Genome Valley major investment completed.
- →Total capex guidance for FY27 remains at INR 600 crores, with further investments in digitalization and modular growth projects.
- →Oncology investment plan: around INR 100 crores for intermediates and INR 200 crores for API side, spread over multiple years.
- →Expansion of peptide intermediate plant in India underway; equipment ordered to scale solid phase synthesis, purification columns, and lyophilization capacity.
- →Genome Valley facility adds about 40% to formulation capacity; currently under scale-up.
- →Focus on strategic investments to enhance complex generics, ADHD, controlled substances, and oncology portfolios.
- →Long-term opportunities being studied in nonsolid dosage areas but at exploratory stage, not committed.
How does Granules India rank vs peers in Pharmaceuticals & Biotechnology?
Pro feature1Granules India
Rev 2Mar 3
See full Pharmaceuticals & Biotechnology sector rankings
How does Granules India rank in Pharmaceuticals & Biotechnology?
Compare Granules India against every Pharmaceuticals & Biotechnology company (Q1 FY27) on revenue, margins and earnings-call signals.